Nektar Therapeutics
NEWS
It’s been a busy week for Nektar Therapeutics with the announcement of an NDA submission to the FDA for NKTR-181 and a non-exclusive, clinical collaboration deal with Syndax Pharmaceuticals.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
Rumors of Nektar Therapeutics being up for sale may have been premature.
Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements.
Immuno-oncology therapeutics have revolutionized certain types of cancer treatments, and they are, in many ways, as close to miracle cures as we’ve seen in decades.
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
Rick Duprey, writing for The Motley Fool, takes a look at three biotech stocks that have quadrupled this year.
Investors have had a decent year, but some have much to be grateful for this Thanksgiving.
JOBS
IN THE PRESS